These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17468185)

  • 1. Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats.
    Hellmold H; Zhang H; Andersson U; Blomgren B; Holland T; Berg AL; Elebring M; Sjögren N; Bamberg K; Dahl B; Westerberg R; Dillner B; Tugwood J; Tugwood J; Roberts R; Lundholm E; Camejo G; Skånberg I; Evans J
    Toxicol Sci; 2007 Jul; 98(1):63-74. PubMed ID: 17468185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferative and molecular effects of the dual PPARalpha/gamma agonist tesaglitazar in rat adipose tissues: relevance for induction of fibrosarcoma.
    Glinghammar B; Berg AL; Bjurström S; Stockling K; Blomgren B; Westerberg R; Skånberg I; Hellmold H; Andersson U
    Toxicol Pathol; 2011 Feb; 39(2):325-36. PubMed ID: 21270424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
    Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
    Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
    Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes.
    Rogue A; Renaud MP; Claude N; Guillouzo A; Spire C
    Toxicol Appl Pharmacol; 2011 Jul; 254(1):18-31. PubMed ID: 21515302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
    Zadelaar AS; Boesten LS; Jukema JW; van Vlijmen BJ; Kooistra T; Emeis JJ; Lundholm E; Camejo G; Havekes LM
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2560-6. PubMed ID: 16931788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies.
    Lindblom P; Berg AL; Zhang H; Westerberg R; Tugwood J; Lundgren H; Marcusson-Ståhl M; Sjögren N; Blomgren B; Öhman P; Skånberg I; Evans J; Hellmold H
    Toxicol Pathol; 2012; 40(1):18-32. PubMed ID: 22131108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tesaglitazar.
    Kamber N; Davis TM
    IDrugs; 2005 Nov; 8(11):927-35. PubMed ID: 16254788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Peroxisome proliferator-activated receptor α/γ agonist tesaglitazar stabilizes atherosclerotic plaque in diabetic low density lipoprotein receptor knockout mice].
    Zhang BC; Li XK; Che WL; Li WM; Hou L; Wei YD; Xu YW
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Feb; 41(2):143-9. PubMed ID: 23710746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist.
    Samuelsson S; Johansson S; Halldórsdóttir S; Stenhoff H; Ohman KP
    J Clin Pharmacol; 2006 Sep; 46(9):1017-22. PubMed ID: 16920896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar.
    Fagerberg B; Schuster H; Birketvedt GS; Tonstad S; Ohman KP; Gause-Nilsson I;
    Diab Vasc Dis Res; 2007 Sep; 4(3):174-80. PubMed ID: 17907107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.
    Tannehill-Gregg SH; Sanderson TP; Minnema D; Voelker R; Ulland B; Cohen SM; Arnold LL; Schilling BE; Waites CR; Dominick MA
    Toxicol Sci; 2007 Jul; 98(1):258-70. PubMed ID: 17426106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice.
    Verreth W; Ganame J; Mertens A; Bernar H; Herregods MC; Holvoet P
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):922-8. PubMed ID: 16456093
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Osinski V; Bauknight DK; Dasa SSK; Harms MJ; Kroon T; Marshall MA; Garmey JC; Nguyen AT; Hartman J; Upadhye A; Srikakulapu P; Zhou A; O'Mahony G; Klibanov AL; Kelly KA; Boucher J; McNamara CA
    Theranostics; 2020; 10(2):585-601. PubMed ID: 31903139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
    Waites CR; Dominick MA; Sanderson TP; Schilling BE
    Toxicol Sci; 2007 Nov; 100(1):248-58. PubMed ID: 17675651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar.
    Hegarty BD; Furler SM; Oakes ND; Kraegen EW; Cooney GJ
    Endocrinology; 2004 Jul; 145(7):3158-64. PubMed ID: 15059948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR Agonists: I. Role of Receptor Subunits in Alcohol Consumption in Male and Female Mice.
    Blednov YA; Black M; Benavidez JM; Stamatakis EE; Harris RA
    Alcohol Clin Exp Res; 2016 Mar; 40(3):553-62. PubMed ID: 26857685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar.
    Sharma S; Sowjanya A; Kumari M; Suryaprakash R; Cynthia G; Suresh J; Chakrabarti R
    Life Sci; 2006 Dec; 80(3):235-44. PubMed ID: 17014868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
    van der Hoorn JW; Jukema JW; Havekes LM; Lundholm E; Camejo G; Rensen PC; Princen HM
    Br J Pharmacol; 2009 Apr; 156(7):1067-75. PubMed ID: 19220285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.